The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

Gut

Volumn 40, Issue 5, 1997, Pages 597-601

  Wettergren, A ^a   Wojdemann M ^a   Meisner, S ^a   Stadil, F ^a   Holst, J J ^b,c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Enterogastrone; Ileal brake; Pentagastrin; Proglucagon; Vagotomy

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; PENTAGASTRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DUODENUM ULCER; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; STOMACH ACID SECRETION; VAGOTOMY; VAGUS NERVE STIMULATION;

EID: 0030962231     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.5.597     Document Type: Article

References (35)

1. Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF. Preglucagon gene expression in pancreas and intestine diversifies at the level of posttanslational processing. J Biol Chem 1986; 261: 11880-6.
2. Ørskov C, Holst JJ, Knuhtsen S, Baldissera FGA, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted seperately from the small intestine, but not pancreas. Endocrinology 1986; 119: 1467-75.
3. Ørskov C, Holst JJ, Poulsen SS, Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia 1987; 30: 874-81.
4. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preglucagon gene. Nature 1983; 30: 368-71.
5. Varndell IM, Bishop A, Sikri E, Uttenthal LO, Bloom SR, Polak JM. Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J Histochem Cytochem 1990; 33: 1080-6.
6. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-66.
7. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Production and secretion of amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes 1994; 43: 535-9.
8. Ørskov C, Wettergren A, Holst JJ. The diurnal secretion of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) is correlated with the secretion of insulin in normal man. Scand J Gastroenterol 1996; 31: 665-70.
9. Göke R, Richter G, Kolligs F, Fehmann HC, Arnold R, Göke B. How do individual meal constituents influence the release of GLP-1 in humans [abstract]? Digestion 1993; 54: 380.
10. Kreymann B, Ghatei MA, Williams G, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; ii: 1300-3.
11. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide-1, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169-74.
12. Komatsu R, Matsuyama T, Namba M. Glucagonostatic and insulinotropic action of glucagonlike peptide-1-(7-36)-amide. Diabetes 1989; 38: 902-5.
13. Hvidberg A, Toft Nielsen M, Hilsted J, Ørskov C, Holst JJ. Effect of glucagon-like peptide-1 (proglucagon 78-107 amide) on hepatic glucose production in healthy man. Metabolism 1994; 43: 104-8.
14. Nauck M, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide-1 [7-37 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7.
15. Ørskov C. Glucagon-like peptide-1 a new hormone of the entero-insular axis. Diabetologia 1992; 35: 701-11.
16. Schjoldager BGT, Mortsen PE, Christiansen J, Ørskov C, Holst JJ. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in man. Dig Dis Sci 1989; 35: 703-8.
17. 2: a physiological inhibitor of gastric acid secretion in man. J Endocrinol 1990; 126: 169-73.
18. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-73.
19. Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 1994; 29: 501-5.
20. Andersen LP, Espersen F, Souckova A, Sedlackova M, Soucek A. Isolation and preliminary evaluation of a low-molecular-mass antigen preparation for improved detection of Helicobacter pylori immunoglobulin G antibodies. Clin Diagn Lab Immunol 1995; 2: 156-9.
21. Henriksen FW, Jögensen SP, Möller S. Interaction between secretin and cholecystokinin on inhibition of gastric secretion in man. Scand J Gastroenterol 1974; 9: 735-40.
22. Widdonson GM, Penton JR. Determination of serum and plasma glucose on "autoanalyzer II" by use of hexokinase reaction. Clin Chem 1972; 18: 299-300.
23. Olbe L, Hamlet A, Dalenbäck J, Fändriks L. A mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 1996; 110: 1386-94.
24. Wettergren A, Maina P, Boesby S, Holst JJ. The effect of GLP-1 and PYY on acid secretion in man [abstract]. Regul Pept 1996; 64: 208.
25. Holst JJ, Skak-Nielsen T, Ørskov C, Poulsen SS. Vagal control of the release of somatostatin, vasoactive intestinal polypeptide, gastrin releasing peptide, and HCl from porcine non-antral stomach. Scand J Gastroenterol 1992; 27: 677-85.
26. Holst JJ, Wettergren A, Wøjdemann M, Poulsen SS, Ørskov C. Glucagon-like peptide-I (GLP-1): an important enterogastrone acting via the central nervous system. Hepatogastroenterology 1995; 42: 1071.
27. Holst JJ, Rasmussen TN, Harling H, Schmidt P. Effect of intestinal inhibitory peptides on vagally induced secretion from isolated perfused porcine pancreas. Pancreas 1993; 8: 80-7.
28. Lorenz DN, Goldman SA. Vagal mediation of the cholecystokinin satiety effect in rats. Physiol Behav 1982; 29: 599-604.
29. Uttenthal LO, Toledano A, Blasquez E. Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain. Neuropeptides 1992; 21: 143-6.
30. Shimizu I, Hirota M, Obhoshi C, Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987; 121: 1076-82.
31. Göke R, Larsen PJ, Mikkelsen JD, Sheikh S. Distribution of GLP-1 binding sites in the rat brain. Evidence that exendin 4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7: 2294-300.
32. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the regulation of feeding. Nature 1996; 379: 69-72.
33. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-1: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995; 358: 319-24.
34. Ørskov C, Poulsen SS, Møller M, Holst JJ. GLP-1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide-1. Diabetes 1996; 45: 832-5.
35. Layer P, Holst JJ, Grandt D, Geobell H. Ileal release of glucagon-like peptide-1 (GLP-1): association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995; 40: 1074-82.